TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed, operable stage IIIB non-small cell lung cancer~  * T4 N0-3 M0 or T1-4 N3 M0 by bronchoscopy and mediastinoscopy (required for assessment of N3 disease) or CT scan or MRI of the thorax~ * Squamous cell~ * Adenosquamous cell~ * Large cell~ * Poorly differentiated~* No prior or concurrent metastatic disease by CT scan or MRI of the brain, bone scan, and abdominal ultrasound or CT scan~* No malignant pleural or pericardial effusion~* No invasion of the aorta, esophagus, myocardium, or supraclavicular nodes~PATIENT CHARACTERISTICS:~Age:~* 18 to 75~Performance status:~* WHO 0-1~Life expectancy:~* Not specified~Hematopoietic:~* WBC at least 4,000/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin normal~* AST and/or ALT no greater than 1.5 times upper limit of normal (ULN)~* Alkaline phosphatase no greater than 2.5 times ULN~Renal:~* Creatinine clearance at least 60 mL/min~Cardiovascular:~* No unstable cardiac disease requiring treatment~* No congestive heart failure~* No angina pectoris (even if medically controlled)~* No significant arrhythmia~* No myocardial infarction within the past 3 months~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No definite contraindications for the use of corticosteroids as premedication~* No preexisting grade 2 or greater peripheral neuropathy~* No active uncontrolled infection~* No uncontrolled diabetes mellitus~* No other prior or concurrent malignancy except non-melanomatous skin cancer or adequately treated carcinoma in situ of the cervix~* No prior significant neurologic or psychiatric disorders including psychotic disorders, dementia, or seizures that would preclude informed consent~* No other serious underlying medical condition that would preclude study participation~* No socioeconomic or geographical circumstances that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Not specified~Endocrine therapy:~* No concurrent corticosteroids except as prophylactic pretreatment medication, treatment for acute hypersensitivity reactions, or chronic treatment (initiated more than 6 months ago) at low-dose (no more than 20 mg methylprednisolone or equivalent)~Radiotherapy:~* No prior radiotherapy to the chest~Surgery:~* See Disease Characteristics~Other:~* At least 30 days since prior treatment in a clinical trial~* No prior cytostatic therapy~* No other concurrent experimental drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven medulloblastoma or supratentorial primitive neuroectodermal tumor~* Average-risk group:~  * Localized tumor with no overt evidence of invasion beyond the posterior fossa~ * Less than 1.5 cm2 residual tumor/imaging abnormality~ * No CNS or extraneural metastasis (confirmed by bone scan)~ * Brain stem invasion allowed if above criteria met~* High-risk group:~  * Metastatic disease within the neuraxis (subarachnoid dissemination) OR greater than 1.5 cm\^2 residual disease at the primary site after surgery~* No bone involvement by bone scan~* Must begin study within 28 days of definitive surgery~PATIENT CHARACTERISTICS:~Age~* 3 to 20 at diagnosis~Performance status~* ECOG 0-3 (except patients with posterior fossa syndrome)~Life expectancy~* Not specified~Hematopoietic~* WBC greater than 3,000/mm\^3~* Absolute neutrophil count greater than 1,500/mm\^3~* Platelet count greater than 100,000/mm\^3~* Hemoglobin greater than 10 g/dL~Hepatic~* Bilirubin less than 1.5 mg/dL~* SGPT less than 1.5 times normal~Renal~* Creatinine less than 1.2 mg/dL OR~* Creatinine clearance greater than 70 mL/min~Other~* Not pregnant or nursing~* Negative pregnancy test~* HIV negative~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy~Endocrine therapy~* Prior corticosteroids allowed~Radiotherapy~* No prior radiotherapy~Surgery~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Average-risk (Type: EXPERIMENTAL): Participants meeting the eligibility requirements for assignment to the average-risk arm.~Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy.
- High-risk (Type: EXPERIMENTAL): Participants meeting the eligibility requirements for assignment to the high-risk arm.~Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent prior to any study-mandated procedure~* Aged from 18 to 45 (inclusive) at screening~* Body mass index (BMI) from 18.0 to 28.0 kg/m2 (inclusive) at screening~* Healthy on the basis of physical examination, cardiovascular assessments and laboratory tests~Exclusion Criteria:~* Any contraindication to the study drug formulations~* History or presence of any disease or condition or treatment, which may put the subject at risk of participation in the study or may interfere with the absorption, distribution, metabolism or excretion of the study drugs~* Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Intravenous selexipag (Pilot phase) (Type: EXPERIMENTAL): Subjects received a 20-minute intravenous (i.v.) infusion of 50 µg selexipag
- Sequence A-B (Main phase) (Type: EXPERIMENTAL): Subjects received a 80-minute i.v. infusion of 200 µg selexipag during Period 1, and 2 tablets of oral selexipag (total dose of 400 µg) as a single administration during Period 2. A washout period of 7 to 10 days separated the i.v. infusion from the oral administration.
- Sequence B-A (Main phase) (Type: EXPERIMENTAL): Subjects received 2 tablets of oral selexipag (total dose of 400 µg) as a single administration during Period 1, and a 80-minute i.v. infusion of 200 µg selexipag during Period 2. A washout period of 7 to 10 days separated the oral administration from the i.v. infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of a Small Aperture Extended Depth of Focus Intraocular Lens

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Minimum 22 years of age;~2. Able to comprehend and have signed a statement of informed consent;~3. Availability, willingness, ability and sufficient cognitive awareness to comply with examination procedures and study visits;~4. Planned crystalline lens removal by phacoemulsification, with or without femtosecond laser-assisted extraction, and posterior chamber IOL implantation in both eyes;~5. Cataractous lens changes as demonstrated by best-corrected visual acuity (BCDVA) of 20/40 or worse either with or without a glare source present;~6. Potential for postoperative BCDVA of 20/25 or better in each eye~7. Clear intraocular media, other than cataract.~Exclusion Criteria:~1. Requiring an IC-8 intraocular lens outside the available spherical power range~2. Pharmacologically dilated pupil size less than 6 mm in either eye;~3. Inability to achieve stable keratometric readings for contact lens wearers~4. Irregular astigmatism in either eye;~5. Preoperative corneal astigmatism \> 1.50 diopters in either eye~6. Active or recurrent anterior segment pathology~7. Presence of ocular abnormalities other than cataract as specified in the protocol~8. Diagnosis of dry eye in which patients are unable to maintain eye comfort or adequate vision even with dry eye medication;~9. Congenital cataracts;~10. Previous corneal or intraocular surgery~11. History of ocular trauma or ocular conditions expected to require retinal laser treatment or other surgical intervention;~12. Systemic conditions as specified in the protocol;~13. Patient is pregnant, plans to become pregnant, or is lactating~14. Concurrent participation or participation in any clinical trial up to 30 days prior to preoperative visit.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- IC-8 IOL Group (Type: EXPERIMENTAL): A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) implanted in the first eye. The AcuFocus IC-8 IOL implanted in the second eye.
- Control Group (Type: ACTIVE_COMPARATOR): A monofocal IOL (TECNIS ZCB00, ZCT150 or ZCT225 or AcrySof IQ SA60WF, SA6AT3 or SA6AT4) bilaterally implanted.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male subject, between the ages of 28 and 55 years, both inclusive~2. Subject had a body mass index (BMI) between 18.5 and 29.9 kg/m2, both inclusive, and a body weight between 50.0 and 99.9 kg, both inclusive, when rounded to the nearest tenth.~3. Subject with total serum calcium ≥ 8.5 mg/dL (≥ 2.125 mmol/L) and serum 25-OH vitamin D ≥ 20 ng/mL (≥ 50 nmol/L)~Exclusion Criteria:~1. Subject was a female.~2. Subject with a hypersensitivity to any component of denosumab or dry natural rubber (a derivative of latex).~3. Subject was confirmed or suspected with infection of coronavirus disease 2019 (COVID-19) at screening, or had had contact with COVID-19 patient within 14 days from screening.~4. Subject had a medical history of and/or current medical condition that can have effect on the study. Details to be discussed with investigator as per Protocol.~   1. Subjects with known risk factors for hypocalcaemia~  2. Subjects with known intolerance to calcium or vitamin D supplements~  3. Subjects with known infection with active hepatitis B, hepatitis C, human immunodeficiency virus, or syphilis~5. Subject had a history of and/or concurrent use of medications including any prior therapy that can have effect on the study. Details to be discussed with investigator as per Protocol.~6. Subjects have or had any therapy that might significantly affect bone metabolism

- Gender: MALE
- Minimum Age: 28 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- CT-P41 (Type: EXPERIMENTAL): a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
- US-licensed Prolia (Type: ACTIVE_COMPARATOR): a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Succinylcholine on Patients Using Statins

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for elective surgery not involving orthopedic procedure, muscle and spinal surgery~* ASA Physical Status 1-3~Exclusion Criteria:~* History of liver failure~* History of renal failure~* History of neuromuscular disease~* Increased intraocular pressure~* Recent major burn~* Multiple trauma~* Susceptibility to or family history of malignant hyperthermia

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Statin use group (Type: OTHER): Patients taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three months.
- non statin use (Type: OTHER): Patients not taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of TAS-102 in Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Has provided written informed consent prior to performance of any study procedure.~* 2. Has definitive histologically or cytologically confirmed advanced or metastatic solid tumor.~* 3. Is able to take medications orally.~* 4. Has adequate organ function (bone marrow, kidney and liver).~* 5. Has Eastern Cooperative Group (ECOG) performance status of 0 or 1.~Exclusion Criteria:~* 1. Has received TAS-102.~* 2. Has suffered serious complications.~* 3. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any prior therapies.~* 4. Has had prior gastrectomy.~* 5. Is a pregnant or lactating female or male who refused using birth control during the clinical trial period and within 6 months after discontinuation of study treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TAS-102 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 or older with a diagnosis of ocular or generalized myasthenia gravis with ocular involvement.~Exclusion Criteria:~* Patients receiving mono-amino-oxidase inhibitors.~* Patients with history of hypertension, cardiac, or cerebrovascular disease.~* Women with confirmed pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Patients (Type: EXPERIMENTAL): Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye. Objective measurements of ptosis will be taken before drug administration and at 1, 5, 30, 60 minutes after drug administration in order to analyze any change in ptosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The study population consisted of treatment-naïve and treatment-experienced adults patients aged 20-65 with HCV RNA level \> 10,000 IU/ml.~Experienced participants included those with a prior relapse or a null response to PegINF/RBV therapy.~-~Exclusion Criteria:Participants with one or more of~* HCV coinfected with hepatitis B virus (HBV)~* human immunodeficiency virus (HIV)~* had any liver disease other than chronic HCV GT4 infection.~* had a history of liver decompensation~* serum a-fetoprotein (AFP) \> 100 ng/ml~* evidence of hepatocellular carcinoma~* major severe illness such as respiratory, renal, heart failure or autoimmune disease~* non-compliance with treatment.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment-naive (Type: ACTIVE_COMPARATOR): Naive Egyptians having HCV GT4 received SOF, RBV, and PegINFα-2 once weekly for 12 weeks~Intervention: 1 DDA: Sofosobuvir (SOF) plus Ribavirin (RBV) and pegylated-interferon (PegINFα-2)
- Treatment-experienced (Type: ACTIVE_COMPARATOR): Experienced Egyptians having HCV GT4 received SOF, RBV, and PegINFα-2 once weekly for 12 weeks~Intervention: 1 DDA: Sofosobuvir (SOF) plus Ribavirin (RBV) and pegylated-interferon (PegINFα-2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with 5 to 20 clinically typical, visible and discrete AKs within a treatment area of sun-damaged skin on either the full face or a contiguous area of approximately 250 cm2 (40 in2) on the chest~* Subjects with minimum 3 clinically typical, visible and discrete AKs within a tracking area of 50 cm2 (8 in2). The tracking area must be within the treatment area~Exclusion Criteria:~* Location of the treatment area (full face or chest) within 5 cm of an incompletely healed wound or within 5 cm of a suspected BCC or SCC~* Treatment with ingenol mebutate gel in the treatment area within the last 12 months~* Lesions in the treatment area that have: atypical clinical appearance (e.g. hyperthrophic, hyperkeratotic or cutaneous horns) and /or, recalcitrant disease (e.g. did not respond to cryotherapy on two previous occasions)~* History or evidence of skin conditions other than the trial indication that would interfere with the evaluation of the trial medication (e.g., eczema, unstable psoriasis, xeroderma pigmentosum)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LEO 43204 gel (Type: EXPERIMENTAL): Treatment once daily for 3 days
- Vehicle gel (Type: PLACEBO_COMPARATOR): Treatment once daily for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Self-affirmation Intervention for People Newly Diagnosed With Advanced Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* within 8 weeks of being informed of diagnosis (primary or recurrent)~* cancer stage III or IV of a primary solid tumor, or a high-grade hematological malignancy, and~* age 18 years or older~Exclusion Criteria:~* medical condition precluding participation (e.g., too ill or fatigued, acute mental confusion as determined by the treating physician), or~* enrolled in other psychosocial experiments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Writing (Type: EXPERIMENTAL): This is a single-group study with one arm only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete